Noninferiority trials aim to prove that the efficacy, defined in terms of a key clinical outcome, of a new treatment is not meaningfully worse than that of an established active control. Noninferiority trials are important when other aspects of care can be improved, such as convenience, toxicity, costs, and safety (nonefficacy benefits). While the motivation for a noninferiority trial is straightforward, the design, execution, and interpretation of these trials is not a trivial task.
View Article and Find Full Text PDFBackground: Cardiac computed tomography (CT) is increasingly used to search for cardioembolic sources of acute ischemic stroke (AIS). We assessed the association between high-risk cardioembolic sources on cardiac CT and AIS.
Methods: We performed a case-control study using data from a prospective cohort including consecutive adult patients with suspected stroke who underwent cardiac CT acquired during the initial stroke imaging protocol between 2018 and 2020.
The food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase, EC 3.1.1.
View Article and Find Full Text PDFThe food enzyme β-fructofuranosidase (β-d-fructofuranoside fructohydrolase; EC 3.2.1.
View Article and Find Full Text PDF